Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized, double-blind, placebo-controlled and open-label extension study of S-812217 in major depressive disorder
jRCT2031210577Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jan 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zuranolone in major depressive disorder (MDD) (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: Change from baseline in HAM-D17 total score on Day 15 of Part A. Started Jan 2022; status: completed.
02
Drugs
zuranolone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2031210577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210577.